Progression-free survival (PFS) was calculated from the date of diagnosis to documented disease progression; observations were censored on the date the patient was last known to be alive or, for patients dying as a result of causes unrelated to lymphoma or treatment, the date of death.
Progression-free survival was calculated from the date of diagnosis to documented disease progression; observations were censored on the date the patient was last known to be alive, or for patients dying as a result of causes unrelated to lymphoma or treatment at the date of death.
In this model the mean utility difference between the progression-free state (P0) and post-progression state (P1), at −0.041util, is smaller than that observed between the point estimates at baseline (P0.1) and first post-progression observation (P1.1), but of threshold statistical significance (p = 0.051).
Paired-samples t tests were used initially to assess within-subject difference in EQ-5D utility at baseline in the progression-free state (P0.0; day 1 of cycle 1) and the first post-progression observation (P1.1).
The much longer lifespan of humans combined with the more complex population of astrocytes, suggest that human astrocytes may participate to an even greater extent to disease progression than observations in rodent models suggest.
The higher frequency of these cells in patients with severe joint involvement and rapid joint progression confirm observations that the frequency of CD4+CD28- T cells may correlate with the risk of occurrence of joint erosions in RA [ 18].
The selection of first follow-up visit subsequent to the diagnosis of first disease progression, excluding observations made on the same day as progression was identified (and before patient knowledge of progression), was made to evaluate the impact of progression on the health utility including patient awareness of progression.
Although future studies are needed to clarify the role of hMena and its isoforms in breast cancer progression, our observation raised the possibility that hMena overexpression may contribute in mediating the activation of various ErbB receptors.
William R Sellers (Dana-Farber Cancer Institute, Boston, MA, USA) showed that receptor tyrosine kinase genes are a particular target of recurrent genomic aberrations during tumorigenic progression, an observation relevant to therapies targeting those receptors or their signaling mediators.
This suggests a regulation of different subsets of miRNAs during tumor progression, an observation consistent with findings in hepatocarcinoma [ 40, 41], where differences in the composition, numbers and relative expression levels of miRNA increase with increasing histological differentiation.
Given the importance of stromal epithelial interactions in determining normal mammary gland development, tissue homeostasis, and tumor progression, the observation that preventive agents can target stroma is not surprising.
